[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Preterm Labor Treatment Market

3.3       Key Market Trends

3.3.1   Drivers

3.3.2   Restraints

3.3.3   Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1   Bargaining Power of Suppliers

3.4.2   Bargaining Power of Buyers

3.4.3   Threat of Substitution

3.4.4   Threat of New Entrants

3.4.5   Competitive Rivalry

3.5       Market Share Analysis

4          Drugs Overview

4.1       Introduction

4.1.1   Market Size & Forecast

4.2       Tocolytic Drugs

4.3       Antibiotics Beta–Mimetic

4.4       Corticosteroids

4.5       Others

5          Dosage Form Overview

5.1       Introduction

5.1.1   Market Size & Forecast

5.2       Tablets & Capsules

5.3       Injection

5.4       Other

6          End User Overview

6.1       Introduction

6.1.1   Market Size & Forecast

6.2       Hospitals

6.3       Nursing Homes

6.4       Pharmacy

7          Regional Overview

7.1       Introduction

7.1.1   Market Size & Forecast

7.2      America

7.2.1   North America

7.2.1.1 U.S.

7.2.1.1.1         By Drugs

7.2.1.1.2         By Dosage Form

7.2.1.1.3         By End User

7.2.1.2 Canada

7.2.1.2.1         By Drugs

7.2.1.2.2         By Dosage Form

7.2.1.2.3         By End User

7.2.1.3 Mexico

7.2.1.3.1         By Drugs

7.2.1.3.2         By Dosage Form

7.2.1.3.3         By End User

7.2.2   South America

7.2.2.1            By Drugs

7.2.2.2            By Dosage Form

7.2.2.3            By End User

7.3      Europe           

7.3.1   Market Size & Forecast (Value)      

7.3.2   Western Europe

7.3.2.1 Germany      

7.3.2.1.1         By Drugs        

7.3.2.1.2         By Dosage Form       

7.3.2.1.3         By End User              

7.3.2.2 France           

7.3.2.2.1         By Drugs        

7.3.2.2.2         By Dosage Form

7.3.2.2.3         By End User     

7.3.2.3 U.K.   

7.3.2.3.1         By Drugs        

7.3.2.3.2         By Dosage Form

7.3.2.3.3         By End User  

7.3.2.4 Italy   

7.3.2.4.1         By Drugs        

7.3.2.4.2         By Dosage Form

7.3.2.4.3         By End User  

7.3.2.5 Spain 

7.3.2.5.1         By Drugs        

7.3.2.5.2         By Dosage Form

7.3.2.5.3         By End User  

7.3.2.6 Rest of Western Europe     

7.3.2.6.1         By Drugs

7.3.2.6.2         By Dosage Form

7.3.2.6.3         By End User

7.3.3   Eastern Europe

7.4      Asia Pacific    

7.4.1   Market Size & Forecast (Value)      

7.4.2   China 

7.4.2.1             By Drugs

7.4.2.2             By Dosage Form

7.4.2.3             By End User

7.4.3   India

7.4.3.1             By Drugs

7.4.3.2             By Dosage Form

7.4.3.3             By End User

7.4.4   Japan 

7.4.4.1             By Drugs        

7.4.4.2             By Dosage Form

7.4.4.3             By End User  

7.4.5   South Korea  

7.4.5.1             By Drugs        

7.4.5.2             By Dosage Form

7.4.5.3             By End User

7.4.6   Australia        

7.4.6.1            By Drugs        

7.4.6.2            By Dosage Form

7.4.6.3            By End User

7.4.7   Rest of Asia-Pacific   

7.4.7.1            By Drugs        

7.4.7.2            By Dosage Form

7.4.7.3            By End User  

7.5       Middle East   

7.5.1   Market Size & Forecast (Value)      

7.5.2   The Middle East

7.5.2.1 UAE

7.5.2.2.1         By Drugs        

7.5.2.2.2         By Dosage Form

7.5.2.2.3         By End User  

7.5.2.2 Qatar

7.5.2.2.1         By Drugs        

7.5.2.2.2         By Dosage Form

7.5.2.2.3         By End User  

7.5.2.3 Rest of Middle East

7.5.2.3.1         By Drugs

7.5.2.3 2         By Dosage Form

7.5.2.3 3         By End User

7.6      Africa 

7.6.1   Market Size & Forecast (Value)      

7.6.2   South Africa

7.6.2.1 South Africa

7.6.2.1.1         By Drugs        

7.6.2.1.2         By Dosage Form

7.6.2.1.3         By End User

7.6.2.2 Ghana

7.6.2.2.1         By Drugs        

7.6.2.2.2         By Dosage Form

7.6.2.2.3         By End User  

7.6.2.3 Nigeria

7.6.2.3.1         By Drugs        

7.6.2.3.2         By Dosage Form

7.6.2.3.3         By End User  

7.6.2.4 Rest of Africa

7.6.2.4.1         By Drugs

7.6.2.4 2         By Dosage Form

7.6.2.4.3         By End User

8.         Company Profile                 

8.1       Merck & Co., Inc

8.1.1   Company Overview 

8.1.2   Financial Performance         

8.1.3   Recent Developments         

8.1.4   Product Portfolio     

8.2       Pfizer Inc

8.2.1   Company Overview 

8.2.2   Financial Performance         

8.2.3   Recent Developments         

8.2.4   Product Portfolio     

8.3       Novartis AG

8.3.1   Company Overview 

8.3.2   Financial Performance         

8.3.3   Recent Developments         

8.3.4   Product Portfolio     

8.4       Sanofi

8.4.1   Company Overview 

8.4.2   Financial Performance         

8.4.3   Recent Developments         

8.4.4   Product Portfolio     

8.5       AstraZeneca

8.5.1   Company Overview 

8.5.2   Financial Performance         

8.5.3   Recent Developments         

8.5.4   Product Portfolio     

8.6       GlaxoSmithKline plc

8.6.1   Company Overview 

8.6.2   Financial Performance         

8.6.3   Recent Developments         

8.6.4   Product Portfolio     

8.7       Cipla Inc.

8.7.1   Company Overview 

8.7.2   Financial Performance         

8.7.3   Recent Developments         

8.7.4   Product Portfolio     



Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports